Company news

Arrowhead Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

August 17, 2020

Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

August 10, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results

August 4, 2020

Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

July 28, 2020

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

July 27, 2020

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

July 8, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results

July 7, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences

May 27, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results

May 6, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences

April 30, 2020

Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given

April 30, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results

April 21, 2020

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis

April 9, 2020

Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread

March 16, 2020

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH

March 2, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences

March 1, 2020

Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

February 4, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results

February 4, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results

January 21, 2020

Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer

January 5, 2020

Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

December 19, 2019

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease

December 15, 2019

Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors

December 12, 2019

Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

December 10, 2019

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

December 5, 2019

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

December 3, 2019

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock

December 1, 2019

Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences

November 25, 2019

Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results

November 24, 2019

Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019

November 17, 2019

Arrowhead Pharmaceuticals Announces Planned Management Transition

November 14, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results

November 10, 2019

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019

November 7, 2019

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference

October 30, 2019

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics

October 17, 2019

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

October 1, 2019

Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences

September 29, 2019

Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

September 15, 2019

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.